ATE374817T1 - Krebszellen-impfstoff - Google Patents

Krebszellen-impfstoff

Info

Publication number
ATE374817T1
ATE374817T1 AT99961831T AT99961831T ATE374817T1 AT E374817 T1 ATE374817 T1 AT E374817T1 AT 99961831 T AT99961831 T AT 99961831T AT 99961831 T AT99961831 T AT 99961831T AT E374817 T1 ATE374817 T1 AT E374817T1
Authority
AT
Austria
Prior art keywords
protein
specific regulator
mhc class
rna molecule
molecule encoding
Prior art date
Application number
AT99961831T
Other languages
English (en)
Inventor
Minzhen Xu
Gang Qiu
Robert Humphreys
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Application granted granted Critical
Publication of ATE374817T1 publication Critical patent/ATE374817T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99961831T 1998-12-04 1999-11-24 Krebszellen-impfstoff ATE374817T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/205,995 US6368855B1 (en) 1996-06-11 1998-12-04 MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression

Publications (1)

Publication Number Publication Date
ATE374817T1 true ATE374817T1 (de) 2007-10-15

Family

ID=22764546

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961831T ATE374817T1 (de) 1998-12-04 1999-11-24 Krebszellen-impfstoff

Country Status (10)

Country Link
US (2) US6368855B1 (de)
EP (1) EP1135482B1 (de)
JP (1) JP4836327B2 (de)
KR (1) KR100689429B1 (de)
CN (1) CN100389196C (de)
AT (1) ATE374817T1 (de)
AU (1) AU771580C (de)
CA (1) CA2354188C (de)
DE (1) DE69937252D1 (de)
WO (1) WO2000034467A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
US20030198626A1 (en) * 2002-04-22 2003-10-23 Antigen Express, Inc. Inhibition of Ii expression in mammalian cells
EP1270732A1 (de) * 2001-06-21 2003-01-02 Schuler, Gerold Transfektion von eukaryotischen Zellen mit linearen Polynukleotiden mittels Elektroporation
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
US11243494B2 (en) 2002-07-31 2022-02-08 Abs Global, Inc. Multiple laminar flow-based particle and cellular separation with laser steering
US20040161417A1 (en) * 2002-08-14 2004-08-19 Eli Gilboa Method of enhancing CD4+ T cell responses
US20060172315A1 (en) * 2005-02-01 2006-08-03 Anderson Amy L Methods for staining cells for identification and sorting
US20060265485A1 (en) * 2005-05-17 2006-11-23 Chai Sek M Method and apparatus for controlling data transfer in a processing system
US7603492B2 (en) * 2005-09-20 2009-10-13 Motorola, Inc. Automatic generation of streaming data interface circuit
SI2161038T1 (sl) 2006-01-26 2014-05-30 Isis Pharmaceuticals, Inc. Sestavki in njihove uporabe, usmerjeni proti huntingtinu
US20080120497A1 (en) * 2006-11-20 2008-05-22 Motorola, Inc. Automated configuration of a processing system using decoupled memory access and computation
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
US10908066B2 (en) 2010-11-16 2021-02-02 1087 Systems, Inc. Use of vibrational spectroscopy for microfluidic liquid measurement
US8961904B2 (en) 2013-07-16 2015-02-24 Premium Genetics (Uk) Ltd. Microfluidic chip
US11796449B2 (en) 2013-10-30 2023-10-24 Abs Global, Inc. Microfluidic system and method with focused energy apparatus
SG11201706777QA (en) 2015-02-19 2017-09-28 Premium Genetics (Uk) Ltd Scanning infrared measurement system
WO2019226790A1 (en) 2018-05-23 2019-11-28 Abs Global, Inc. Systems and methods for particle focusing in microchannels
EP3899489B1 (de) 2018-12-21 2025-04-09 ABS Global, Inc. System und verfahren zur identifizierung einer subpopulation
EP3955735B1 (de) 2019-04-18 2024-05-22 ABS Global, Inc. System und verfahren zur kontinuierlichen zugabe eines kryoprotektivums
US11628439B2 (en) 2020-01-13 2023-04-18 Abs Global, Inc. Single-sheath microfluidic chip
US12497648B2 (en) 2020-10-21 2025-12-16 Abs Global, Inc. Methods and systems for processing genetic samples to determine identity or detect contamination
WO2022108840A1 (en) 2020-11-23 2022-05-27 Abs Global, Inc. Modular flow cytometry systems and methods of processing samples
USD1118965S1 (en) 2021-11-12 2026-03-17 Abs Global, Inc. Flow cytometry device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US5726020A (en) 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
EP0911400A1 (de) * 1997-03-07 1999-04-28 Mochida Pharmaceutical Co., Ltd. Antisensverbindungen gegen cd14
WO1998050540A1 (en) * 1997-05-05 1998-11-12 Hoechst Marion Roussel Deutschland Gmbh MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression

Also Published As

Publication number Publication date
JP2002531582A (ja) 2002-09-24
KR20010089545A (ko) 2001-10-06
CA2354188A1 (en) 2000-06-15
CN100389196C (zh) 2008-05-21
AU771580C (en) 2005-08-04
EP1135482A4 (de) 2002-11-06
US6368855B1 (en) 2002-04-09
KR100689429B1 (ko) 2007-03-08
DE69937252D1 (de) 2007-11-15
EP1135482A1 (de) 2001-09-26
CA2354188C (en) 2013-07-09
AU771580B2 (en) 2004-03-25
AU1832900A (en) 2000-06-26
WO2000034467A1 (en) 2000-06-15
CN1332799A (zh) 2002-01-23
EP1135482B1 (de) 2007-10-03
JP4836327B2 (ja) 2011-12-14
US20030054365A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE69937252D1 (de) Krebszellen-impfstoff
Raben et al. A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope.
Sæterdal et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
Hos et al. Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
Brahms et al. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies
Kocher et al. Identification and intracellular location of MAGE-3 gene product
Huang et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
Kawamoto et al. Complete nucleotide sequence of cDNA and deduced amino acid sequence of rat liver arginase.
Timpte et al. Porcine submaxillary gland apomucin contains tandemly repeated, identical sequences of 81 residues.
Häcker et al. Cell type‐specific activation of mitogen‐activated protein kinases by CpG‐DNA controls interleukin‐12 release from antigen‐presenting cells
Cormier et al. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
KR970707269A (ko) 코리네형 박테리아에서 유전자 발현을 조절하는 dna(dna which regulates gene expression in coryne-form bacteria)
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
ATE471373T1 (de) Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna
Torikai et al. A novel HLA-A* 3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene
EP1012173B1 (de) Isolierte decapeptide, die an hla moleküle binden, sowie deren verwendung
RU2218181C2 (ru) ЧЕЛОВЕЧЕСКИЙ СЕМАФОРИН L(H-Sema-L) И СООТВЕТСТВУЮЩИЕ СЕМАФОРИНЫ В ДРУГИХ ВИДАХ
DE69840333D1 (de) 2-m übergang des zellzyklus
DK0796104T3 (da) Levering af nukleinsyremolekyler til slimhindevæv
HUP9902710A2 (hu) Rekombináns sertés-poxvírus
JP2023017853A (ja) 新規な癌抗原及び方法
DE69927249D1 (de) Induzierendes alphavirengen- expressionssystem
ES2267812T3 (es) Materiales y metodos que relacionan respuestas inmunes con proteinas de fusion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties